


## PHARMACEUTICAL 2021

## ELI LILLY & Co Rank 262 of 402







## PHARMACEUTICAL 2021

## ELI LILLY & Co Rank 262 of 402



The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 76% points. The greatest weakness of ELI LILLY & Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is 37%, being 10% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	17,462,100
Cost of Goods Sold	5,483,300
Intangible Assets	11,216,500
Liabilities, Current	12,481,600
Liabilities, Non-Current	28,326,300
Other Assets	9,272,600
Other Compr. Net Income	27,200
Other Expenses	655,900
Other Liabilities	0
Other Net Income	0
Other Revenues	24,539,800
Property and Equipment	8,681,900
Research and Development	6,085,700
Selling, General and Administrative Expense	6,121,200

Output Variable	Value in 1000 USD
Assets	46,633,100
Liabilities	40,807,900
Expenses	18,346,100
Revenues	24,539,800
Stockholders Equity	5,825,200
Net Income	6,193,700
Comprehensive Net Income	6,207,300
Economic Capital Ratio	37%

